A total of 43 innovative new medicines are anticipated to be approved or listed in Japan this year, according to a survey by Jiho. At the center of attention are some highly innovative, but probably ultra-expensive, gene therapies, as well…
HOME > Drug Approval & Reimbursement in 2023
Drug Approval & Reimbursement in 2023
-
Japan Approves Label Expansions for Rexulti, Rituxan, and More
December 25, 2023
-
Leqembi to Cost 2.98 Million Yen per Year, Re-Pricing Might Be Triggered on Patient Upswing
December 14, 2023
-
Shionogi’s Novel Antibiotic Fetroja Gets Fast-Track Listing for Dec. 20
December 14, 2023
-
Leqembi OK’ed for Listing on Dec. 20; Peak Sales Put at 98.6 Billion Yen
December 13, 2023
-
Japan Approves Meiji’s COVID Vaccine, Daiichi Sankyo’s XBB-Tailored Jab
November 28, 2023
-
Japan Approves Label Expansions for Opdivo, Adcetris, and More
November 27, 2023
-
1st G-Lasta Biosimilar Gets Japan Listing, Stelara Follow-On Not on Roster
November 21, 2023
-
Listing OK’ed for Phesgo, Leqvio, Epkinly, and More; 30 Billion-Plus Yen Peak Sales for 3 Meds
November 16, 2023
-
Wegovy Lands Reimbursement Listing in Japan 8 Months after Approval
November 16, 2023
-
Japan Approves Multiple Firsts, Leqembi, Arexvy, Leqvio, and More
September 26, 2023
-
Japan Approves Eisai/Biogen’s Alzheimer’s Drug Leqembi
September 25, 2023
-
Moderna’s Omicron XBB.1.5 Vaccine Snags Japan Approval
September 12, 2023
-
Japan Approves Pfizer’s Omicron XBB.1.5 Vaccine, Moderna’s Still under Review
September 4, 2023
-
Chuikyo OKs Listing of Litfulo and More; 10 Billion-Plus Yen Peak Sales for Pfizer, Sobi Meds
August 24, 2023
-
Luxturna Priced at 49.6 Million Yen per Vial, Peak Sales Put at 500 Million Yen with 5 Patients
August 24, 2023
-
Japan Approves Enhertu’s NSCLC Use, More Label Expansions
August 24, 2023
-
Japan OKs 1st Homemade COVID Jab, but No Supply Planned; Daiichi to Pursue XBB.1 Update
August 3, 2023
-
Japan Approves Gilead’s HIV Med Sunlenca, Listing Set for Aug. 9
August 2, 2023
-
Japan OKs Oncaspar, Lytgobi, Litfulo, Rinvoq/Keytruda Label Expansions and More
June 27, 2023
-
Japan Approves Novartis’ Gene Therapy Luxturna for Rare Eye Disease
June 27, 2023
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…